ARDC Research Link Australia Research Link Australia   BETA Research
Link
Australia
  • ARDC Newsletter Subscribe
  • Contact Us
  • Home
  • About
  • Feedback
  • Explore Collaborations
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation

Need help searching? View our Search Guide.

Advanced Search

Current Selection
Scheme : Project Grants
Research Topic : T Cell Receptor
Australian State/Territory : NSW
Clear All
Filter by Field of Research
Cancer Cell Biology (5)
Innate Immunity (3)
Haematology (2)
Immunology not elsewhere classified (2)
Medical Virology (2)
Signal Transduction (2)
Solid Tumours (2)
Biochemistry and Cell Biology not elsewhere classified (1)
Cell Development, Proliferation and Death (1)
Cell and Nuclear Division (1)
Cellular Immunology (1)
Cellular Interactions (incl. Adhesion, Matrix, Cell Wall) (1)
Oncology and Carcinogenesis not elsewhere classified (1)
Peripheral Nervous System (1)
Protein Trafficking (1)
Filter by Socio-Economic Objective
Search did not return any results.
Filter by Funding Provider
National Health and Medical Research Council (26)
Filter by Status
Closed (26)
Filter by Scheme
Project Grants (26)
Filter by Country
Australia (26)
Filter by Australian State/Territory
NSW (26)
VIC (4)
ACT (1)
QLD (1)
SA (1)
WA (1)
  • Researchers (0)
  • Funded Activities (26)
  • Organisations (30)
  • Funded Activity

    Protecting Against Malaria Through Liver-resident Memory T Cells

    Funder
    National Health and Medical Research Council
    Funding Amount
    $1,196,853.00
    Summary
    We have shown that formation of liver-resident memory T cells (Trm), a newly discovered type of immune cells, can be induced by an innovative vaccination strategy called prime and trap for highly efficient protection against malaria in mice. Here, we will enhance prime and trap vaccination efficacy by defining the conditions that maximize liver Trm-mediated protection and will characterize simian and human liver Trm cells, paving the way to create the most efficient human malaria vaccine to date
    More information
    Funded Activity

    Initial Interactions Of Herpes Simplex Virus With Innate Immune Cells In Human Skin

    Funder
    National Health and Medical Research Council
    Funding Amount
    $522,589.00
    Summary
    Herpes simplex viruses 1 and 2 cause widespread and occasionally serious diseases including genital herpes, neonatal death and encephalitis. Current vaccine candidates are at best partially effective. This grant will examine the way that the virus enters, initially spreads within the skin and interacts with immune cells to help determine which cells should be stimulated by vaccines.
    More information
    Funded Activity

    Deciphering How TCR Affinity Regulates CD4 T Cell Help In Immunity And Autoimmunity

    Funder
    National Health and Medical Research Council
    Funding Amount
    $850,885.00
    Summary
    Immune responses require the coordinated interaction and cross-talk between two types of white blood cells known as CD4 and CD8 T cells. A dysregulated interaction between these cells could be the cause of autoimmune and persistent infections by pathogens leading to chronic diseases. The aim of this proposal is to provide a deeper understanding of CD4/CD8 T cell interactions to improve immune outcomes in many chronic diseases in which interaction between these two immune cells is critical.
    More information
    Funded Activity

    Developing A New Strategy For Treating Demyelinating Peripheral Diseases

    Funder
    National Health and Medical Research Council
    Funding Amount
    $496,250.00
    Summary
    Incomplete remyelination is a significant component of the persistent clinical disability of peripheral demyelinating neuropathy, contributing to conduction deficits and the secondary axonal damage. A crucial therapeutic challenge is to identify ways to promote remyelination. This project aims to develop a new strategy and a novel clinically relevant target for treating peripheral demyelinating neuropathy.
    More information
    Funded Activity

    Pushing AR Toward Better Outcomes In Breast And Prostate Cancers

    Funder
    National Health and Medical Research Council
    Funding Amount
    $998,754.00
    Summary
    Breast and prostate cancers kill >6000 Australians each year. These cancers are strikingly similar, both driven by hormone receptors that have ‘gone bad’. Current therapies aim to eradicate the receptors. While often effective, therapeutic resistance is common and results in fatal disease. We aim to develop new, less toxic treatments that switch receptor behaviour from good to bad, without destroying them. This should improve quality of life, while preventing drug resistance and loss of lives .... Breast and prostate cancers kill >6000 Australians each year. These cancers are strikingly similar, both driven by hormone receptors that have ‘gone bad’. Current therapies aim to eradicate the receptors. While often effective, therapeutic resistance is common and results in fatal disease. We aim to develop new, less toxic treatments that switch receptor behaviour from good to bad, without destroying them. This should improve quality of life, while preventing drug resistance and loss of lives.
    Read more Read less
    More information
    Funded Activity

    Dual Targeting Of The Androgen Receptor For Effective And Durable Control Of Lethal Prostate Cancer

    Funder
    National Health and Medical Research Council
    Funding Amount
    $946,177.00
    Summary
    Preventing binding of androgens to the androgen receptor is the mainstay treatment for advanced prostate cancer, but resistance inevitably develops and the disease becomes lethal. We will develop a new drug that targets a part of the androgen receptor unrelated to its androgen binding function to overcome resistance to current therapy. As this drug will be effective in all stages of prostate cancer, it has high potential to improve survival outcomes for men with prostate cancer.
    More information
    Funded Activity

    The Unique Nature Of Gamma Delta T Cell Recognition Resolved Through Interaction With H2-Q10

    Funder
    National Health and Medical Research Council
    Funding Amount
    $699,031.00
    Summary
    The liver is important for both digestion and immunity. Given these opposing functions, the liver must exert control points that prevent the immune system from recognising food products. We have now identified a new molecular target that controls the development of immune cells in the liver.
    More information
    Funded Activity

    Redirecting T-cells For Immunotherapy Of Leukaemia And Lymphoma By The Expression Of A CD19-specific Chimeric Antigen Receptor Using The PiggyBac Transposon Gene Modification System

    Funder
    National Health and Medical Research Council
    Funding Amount
    $374,876.00
    Summary
    Most lymphomas respond to therapy but then relapse. Immune cells can attack and kill virus related lymphomas. However, most lymphomas are NOT virus related. We will create immune cells targeting these virus negative lymphomas by inserting artificial receptors into the immune cells. These receptors attach to the lymphoma and activate the immune cells. The immune cells will home to the lymphoma, kill lymphoma cells and persist in the body for many years, preventing lymphoma relapse.
    More information
    Funded Activity

    Ubiquitin And SUMO DNA Damage Response Signalling At Deprotected Telomeres During The Cell Cycle

    Funder
    National Health and Medical Research Council
    Funding Amount
    $302,627.00
    Summary
    Following genome damage cells stop the cell division process and initiate DNA repair. We discovered that at specific times during cell division his does not happen if the damage signals originate from the chromosome ends (i.e. “telomeres”). We anticipate this is necessary to prevent genomic instability in healthy cells and may be driving genomic instability in cancer cells. Experiments described here will elucidate the molecular mechanisms and biological significance of our observation.
    More information
    Funded Activity

    Investigating The Cellular Response To Iron-Depletion: The Trilogy Of ASK1, Thioredoxin And Ribonucleotide Reductase

    Funder
    National Health and Medical Research Council
    Funding Amount
    $552,572.00
    Summary
    Iron is crucial for many essential biological processes. Recently, we demonstrated that iron-depletion can affects important signalling pathways (e.g., JNK and p38) that play important roles in growth arrest and apoptosis. This study is designed to investigate the cellular and molecular effects of iron depletion which currently remains unclear. The research is crucial for understanding: (1) the effects of iron deficiency and (2) for understanding the effects of iron chelators that are used for t .... Iron is crucial for many essential biological processes. Recently, we demonstrated that iron-depletion can affects important signalling pathways (e.g., JNK and p38) that play important roles in growth arrest and apoptosis. This study is designed to investigate the cellular and molecular effects of iron depletion which currently remains unclear. The research is crucial for understanding: (1) the effects of iron deficiency and (2) for understanding the effects of iron chelators that are used for treating various diseases.
    Read more Read less
    More information

    Showing 1-10 of 26 Funded Activites

    • 1
    • 2
    • 3
    Advanced Search

    Advanced search on the Researcher index.

    Advanced search on the Funded Activity index.

    Advanced search on the Organisation index.

    National Collaborative Research Infrastructure Strategy

    The Australian Research Data Commons is enabled by NCRIS.

    ARDC CONNECT NEWSLETTER

    Subscribe to the ARDC Connect Newsletter to keep up-to-date with the latest digital research news, events, resources, career opportunities and more.

    Subscribe

    Quick Links

    • Home
    • About Research Link Australia
    • Product Roadmap
    • Documentation
    • Disclaimer
    • Contact ARDC

    We acknowledge and celebrate the First Australians on whose traditional lands we live and work, and we pay our respects to Elders past, present and emerging.

    Copyright © ARDC. ACN 633 798 857 Terms and Conditions Privacy Policy Accessibility Statement
    Top
    Quick Feedback